Skip to main content
. Author manuscript; available in PMC: 2022 Aug 18.
Published in final edited form as: Sci Transl Med. 2021 Aug 18;13(607):eabf7201. doi: 10.1126/scitranslmed.abf7201

Fig. 6. bNAbs–Rh-α4β7 treatment increases T cell responses with no change in total anti–HIV Env antibodies.

Fig. 6.

(A) Antibody titers against the SHIVSF162P3 gp140 trimer were measured before week 10 p.i. and after week 17 p.i. in the bNAbs-only and bNAbs–Rh-α4β7 treatment groups. Results are compared by two-way ANOVA with Sidak’s multiple comparisons test. (B) Shown is the frequency of CD4+ T cells (left) and CD8+ T cells (right) secreting IFN-γ, TNF-α, or both, after PBMC stimulation for 6 hours with CD28/CD49d and a HIV consensus B envelope peptide pool, a gag pool, or a pool of 15-mer overlapping peptides from the V2 loop of the SHIVSF162P3 Env. Data from the two treatment groups are compared by Kruskal-Wallis test and the results of the Dunn’s multiple comparisons post hoc test. *P < 0.05. Bars represent means ± SD.